AI Engines For more Details: Perplexity Kagi Labs You
Prostate Cancer: Nilutamide is classified as an antiandrogen medication and is used in combination with other treatments (such as surgical castration or luteinizing hormone-releasing hormone agonists) for the treatment of metastatic prostate cancer in men. It works by blocking the effects of androgens (male hormones) on the prostate cancer cells, thereby slowing down the growth and spread of the cancer.
Androgen Blockade: Nilutamide competitively inhibits the binding of androgens (such as testosterone) to androgen receptors in prostate cancer cells. By blocking the androgen receptors, nilutamide interferes with the signaling pathways that promote the growth and survival of prostate cancer cells. This antiandrogenic effect helps to suppress the progression of prostate cancer and may lead to a reduction in tumor size and serum prostate-specific antigen (PSA) levels.
Metastatic Disease: Nilutamide is particularly beneficial in the treatment of metastatic prostate cancer, where the cancer has spread beyond the prostate gland to other parts of the body, such as the bones, lymph nodes, or distant organs. By inhibiting the growth of cancer cells and reducing the production of PSA, nilutamide may help slow down disease progression and improve survival outcomes in men with metastatic prostate cancer.
Symptom Relief: In addition to its anticancer effects, nilutamide may also provide symptom relief in men with advanced prostate cancer. By reducing the size of the prostate tumor and alleviating pressure on surrounding tissues and organs, nilutamide can help alleviate symptoms such as urinary obstruction, bone pain, and other complications associated with advanced prostate cancer.
Side Effects: Common side effects of nilutamide may include hot flashes, decreased libido, erectile dysfunction, breast tenderness or enlargement (gynecomastia), nausea, vomiting, diarrhea, fatigue, and liver function abnormalities. Serious adverse effects such as hepatotoxicity (liver damage), interstitial pneumonitis, and visual disturbances (including impaired dark adaptation and night blindness) are rare but may occur with prolonged use of nilutamide.
Monitoring: Patients receiving nilutamide therapy require regular monitoring of liver function tests (LFTs), serum PSA levels, and ocular examinations to detect and manage any potential adverse effects or complications associated with treatment. Dosage adjustments or discontinuation of nilutamide may be necessary in cases of severe adverse reactions or hepatic dysfunction.
Contraindications: Nilutamide is contraindicated in individuals with a history of hypersensitivity or allergic reactions to the medication, as well as in pregnant women or women of childbearing potential due to the risk of fetal harm. It should be used with caution in patients with preexisting liver disease or impairment.
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
